Patient demographics (n = 201).
| Values | |
|---|---|
| Female sex | 135 (67) |
| Age, yrs, mean (SD) | 58.4 (14.2) |
| Previous COVID-19 infection | 7 (3.5) |
| Disease duration, yrs, median (IQR) | 7.9 (3.0–8.0) |
| Diagnosis | |
| Rheumatoid arthritis | 63 (31) |
| Systemic lupus erythematosus | 20 (10) |
| AAV (GPA/EGPA) | 61/4 (32) |
| Polymyositis/dermatomyositis | 28 (14) |
| Systemic sclerosis | 10 (5) |
| Other RDs | 14 (7) |
| mRNA vaccine used | |
| Pfizer/BioNTech | 195 (97) |
| Moderna | 6 (3) |
| Time from vaccination to blood sample, d, median (IQR) | 42 (12–64) |
| DMARD treatment | |
| None | 52 (25) |
| Prednisone | 84 (42) |
| Prednisone dose, mg, median (IQR) | 5 (5–10) |
| Methotrexate | 51 (25) |
| Hydroxychloroquine | 22 (11) |
| Azathioprine | 21 (10) |
| Leflunomide | 11 (5) |
| Mycophenolate mofetil | 9 (4) |
| Ig | 6 (3) |
| Cyclophosphamide | 2 (1) |
| Sulfasalazine | 1 (0.5) |
| Biologic treatment | |
| None | 35 (17) |
| RTX within last 15 months | 145 (72) |
| TNF inhibitors | 6 (3) |
| JAK inhibitors | 6 (3) |
| IL-6 inhibitors | 5 (2) |
| Abatacept | 4 (2) |
| Previous RTX treatment, median (IQR) | |
| No. of infusions | 5 (2–8) |
| Cumulative total dose, mg | 4000 (2000–8000) |
| Total treatment timea, d | 505 (30–1532) |
Values are expressed as n (%) unless otherwise indicated.
↵aTime between the first and last RTX treatment before vaccination. AAV: antineutrophil cytoplasmic antibody–associated vasculitis; COVID-19: coronavirus disease 2019; DMARD: disease-modifying antirheumatic drug; EGPA: eosinophilic granulomatosis with polyangiitis; GPA: granulomatosis with polyangiitis; IL: interleukin; JAK: Janus kinase; RD: rheumatic disease; RTX: rituximab; TNF: tumor necrosis factor.